TP53 and cancer: There is evidence that anti-p53 (auto) antibodies isolated from cancer patients are sometimes unable to recognize wild-type p53; and most commercial antibodies and vaccines are directed to the p53 terminal domain epitopes which is similar in both wild-type and mutant p53 rather than the “core” DNA-binding domain where most of the mutations occur [69].